Long-term nonprogression of HIV infection in children: Evaluation of the ANRS prospective French Pediatric Cohort

Clinical Infectious Diseases

Volumn 45, Issue 6, 2007, Pages 785-794

  Warszawski, Josiane ^a,b,c,d   Lechenadec, Jérôme ^a   Faye, Albert ^e   Dollfus, Catherine ^f   Firtion, Ghislaine ^g   Meyer, Laurence ^a,b,c   Douard, Danielle ^j   Monpoux, Fabrice ^k   Tricoire, Joëlle ^l   Benmebarek, Yassine ^a   Rouzioux, Christine ^h   Blanche, Stéphane ^h,i  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

^d INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g NONE   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j HÔPITAL PELLEGRIN   (France)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^l CHU PURPAN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ARTICLE; BIRTH WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PREMATURITY; PRIORITY JOURNAL; SEROLOGY; SURVIVAL RATE; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 34548487496     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521165     Document Type: Article

References (41)

1. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV-1 Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retroviral 1997; 14:442-50.
2. Salvini F, Scarlatti G, Bossi A, et al. Follow-up of vertically HIV-1-infected long-surviving children. AIDS Patient Care STDS 2001; 15:59-65.
3. Casartelli N, Di Matteo G, Argentini C, et al. Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS 2003; 17:1291-301.
4. Chakraborty R, Reinis M, Rostron T, et al. Nef gene sequence variation among HIV-1-infected african children. HIV Med 2006; 7:75-84.
5. Paul ME, Mao C, Charucat M, et al. Predictors of immunologic long-term nonprogression in HIV-1-infected children: implications for initiating therapy. J Allergy Clin Immunol 2005; 115:848-55.
6. Alexander L, Cuchura L, Simpson BJ, Andiman WA. Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors. Pediatr Infect Dis J 2006; 25:135-41.
7. Strathdee SA, Veugelers PJ, Page-Schafer KA, et al. Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS 1996; 10:959-65.
8. Easterbrook PJ. Long-term non-progression in HIV infection: definitions and epidemiological issues. J Infect 1999; 38:71-3.
9. Rodes B, Toro C, Paxinos E, et al. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004; 18:1109-16.
10. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L; SEROCO Study Group. Undetectable viremia without antiretroviral therapy in patients with HIV-1 seroconversion: an uncommon phenomenon? Clin Infect Dis 2005; 40:1350-4.
11. Kaslow RA, Dorak T, Tang JJ. Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 2005; 191:S68-77.
12. Shioda T, Nakayama EE. Human genetic polymorphisms affecting HIV-1 diseases. Int J Hematol 2006; 84:12-7.
13. Crotti A, Neri F, Corti D, et al. Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation. J Virol 2006; 80:10663-74.
14. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent HIV-1 from a subset of elite suppressors. J Virol 2006; 81:2508-18.
15. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994; 43:1-10.
16. Dunn D; HIV-1 Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1605-11.
17. Blanche S, Mayaux MJ, Rouzioux C, et al. Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med 1994; 330:308-12.
18. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts: Rapport 2006. Médecine- Sciences. Flammarion. Available at: http://www.sante.gouv.fr. Accessed July 2007
19. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343:871-81.
20. Paediatric European Network for treatment of AIDS (PENTA). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001; 84:230-6.
21. Kalbleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons, 1980.
22. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17).
23. Ciuta ST, Boros S, Napoli PA, Pezzotti P, Rezza G. Predictors of survival in children with acquired immunodeficiency syndrome in Italy, 1983 to 1995. AIDS Patient Care STDS 1998; 12:629-37.
24. Morris CR, Araba-Owoyele L, Spector SA, Maldonado YA. Disease patterns and survival after acquired immunodeficiency syndrome diagnosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:321-8.
25. Lambotte O, Boufassa F, Madec Y, et al. HIV-1 controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-6.
26. Mayaux MJ, Burgard M, Teglas JP, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV-1 infection Study Group. JAMA 1996; 275:606-10.
27. + T cell counts in children born in Europe. Pediatr Infect Dis J 2005; 24:595-600.
28. Jiao Y, Xie J, Li T, et al. Correlation between gag-specific CD8 T-cell responses, viral load, and the CD4 count in HIV-1 infection is dependent on disease status. J Acquir Immune Defic Syndr 2006; 42:263-8.
29. Martinez V, Costagliola D, Bonduelle O, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005; 191:2053-63.
30. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006; 80:4758-70.
31. Migueles SA, Laborico AC, Imamichi H, et al. The differential ability of HLA B*5701+ long-term non progressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 2003; 77:6889-98.
32. Holodniy M. HIV-1 load quantitation: a 17-year perspective. J Infect Dis 2006; 194:s38-44.
33. Candotti D, Costagliola D, Joberty C, et al. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999; 58:256-63.
34. + T cell counts. J Infect Dis 2005; 192:46-55.
35. Misrahi M, Teglas JP, N'Go N, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA 1998; 279:277-80.
36. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, et al. Effects of CCR5-delta 32 and CCR2-641 alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS 2003; 17:1631-8.
37. Tiemessen CT, Kuhn L. Immune pathogenesis of pediatric HIV-1 infection. Curr HIV/AIDS Rep 2006; 3:13-9.
38. Papathanasopoulos MA, Patience T, Meyers TM, McCutchan FE, Morris L. Full-length genome characterization of HIV-1 type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. AIDS Res Hum Retroviruses 2003; 19:1033-7.
39. Foster C, Lyall EG. Children with HIV-1: improved mortality and morbidity with combination antiretroviral therapy. Curr Opin Infect Dis 2005; 18:253-9.
40. De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV-1 infection in Children and the Italian National AIDS registry. JAMA 2000; 284:190-7.
41. Faye A, Le Chenadec J, Dofffus C, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV-1 type 1. Clin Infect Dis 2004; 39:1692-8.